183 related articles for article (PubMed ID: 27001802)
1. Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine.
Harris JB
Clin Infect Dis; 2016 Jun; 62(11):1336-7. PubMed ID: 27001802
[No Abstract] [Full Text] [Related]
2. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
[TBL] [Abstract][Full Text] [Related]
4. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
Lagos R; Avendaño A; Prado V; Horwitz I; Wasserman S; Losonsky G; Cryz S; Kaper JB; Levine MM
Infect Immun; 1995 Feb; 63(2):707-9. PubMed ID: 7822046
[TBL] [Abstract][Full Text] [Related]
5. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
Jackson SS; Chen WH
Future Microbiol; 2015; 10(8):1271-81. PubMed ID: 26228388
[TBL] [Abstract][Full Text] [Related]
6. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
Wasserman SS; Losonsky GA; Noriega F; Tacket CO; Castañeda E; Levine MM
Vaccine; 1994 Aug; 12(11):1000-3. PubMed ID: 7975839
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
[TBL] [Abstract][Full Text] [Related]
9. Live oral vaccines against cholera: an update.
Levine MM; Kaper JB
Vaccine; 1993; 11(2):207-12. PubMed ID: 8438619
[TBL] [Abstract][Full Text] [Related]
10. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
Viret JF; Dietrich G; Favre D
Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
[TBL] [Abstract][Full Text] [Related]
11. Experience with registered mucosal vaccines.
Dietrich G; Griot-Wenk M; Metcalfe IC; Lang AB; Viret JF
Vaccine; 2003 Jan; 21(7-8):678-83. PubMed ID: 12531339
[TBL] [Abstract][Full Text] [Related]
12. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.
Cryz SJ; Que JU; Levine MM; Wiedermann G; Kollaritsch H
Infect Immun; 1995 Apr; 63(4):1336-9. PubMed ID: 7890391
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.
Cryz SJ; Levine MM; Losonsky G; Kaper JB; Althaus B
Infect Immun; 1992 Sep; 60(9):3916-7. PubMed ID: 1500200
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G
BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807
[TBL] [Abstract][Full Text] [Related]
17. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
[TBL] [Abstract][Full Text] [Related]
18. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
[TBL] [Abstract][Full Text] [Related]
19. Cholera vaccines.
Ryan ET; Calderwood SB
Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
[TBL] [Abstract][Full Text] [Related]
20. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR.
Herzog C
Travel Med Infect Dis; 2016; 14(4):373-7. PubMed ID: 27425792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
